Patents Assigned to Allergan, Inc.
  • Presbyopia treatments
    Patent number: 10610518
    Abstract: Described herein are methods and compositions for the treatment of ocular conditions and for the improvement of vision parameters using pharmaceutically acceptable ophthalmic pilocarpine formulations. A nonlimiting example of an ocular condition that may be treated with the methods and compositions disclosed herein is presbyopia.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: April 7, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Michael R. Robinson, Mohammed Dibas, Jaya Giyanani, Anuradha Gore, Sungwook Lee, Haixia Liu, Aileen Morgan, Jihao Zhou
  • Prevention and treatment of ocular side effects with a cyclosporin
    Patent number: 10610565
    Abstract: Therapeutic methods including administration of cyclosporin to an eye of a mammal in combination with administration of a therapeutically active agent effective for treatment of a cancer to said mammal to treat an ocular condition associated with the use of said therapeutically active agent are disclosed herein.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 7, 2020
    Assignee: Allergan, Inc.
    Inventors: Gregg Feinerman, Neil Barth, Rhett M. Schiffman, Pamela S. Barnett
  • Dissolvable microneedles for skin treatment
    Patent number: 10603477
    Abstract: A skin treatment device is provided including bioerodible polymeric microneedles which are designed to more effectively deliver beneficial agents to the skin. The device includes a flexible substrate and an arrangement, for example, an array, of microneedles projecting from the substrate.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: March 31, 2020
    Assignee: Allergan, Inc.
    Inventors: Justin J. Schwab, Michael Augarten, Zachary Dominguez, Ethan Franklin, Edwin J. Kayda, Jason Metzner
  • Nucleic acids encoding anti-complement Factor Bb antibodies
    Patent number: 10604563
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: March 31, 2020
    Assignee: Allergan, Inc.
    Inventors: Yanbin Liang, Chen Li, Iris Lee, Victor M. Guzman
  • Methods for treating headache
    Patent number: 10603366
    Abstract: A headache can be treated effectively by administration of a botulinum toxin to a patient at specific muscles using specific doses.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: March 31, 2020
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Mitchell F. Brin
  • Aspiration and injection device
    Patent number: 10596321
    Abstract: An aspiration and injection device is provided that can allow for ergonomic, safe, and precise aspiration of a target site and ejection of a medicament to the target site. The device can include a syringe barrel, a flange extender couplable to the barrel, and plunger that can be engaged by a hand and/or one or more finger of a user to perform aspiration and injection at a target site.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: March 24, 2020
    Assignee: Allergan, Inc.
    Inventors: Bastien Mandaroux, Shushuo Wu, Lance Hussey
  • Method of treating AMD in patients refractory to anti-VEGF therapy
    Patent number: 10568934
    Abstract: Disclosed herein are methods for the treatment of a patient having an ocular conditions such as age-related macular degeneration or diabetic macular edema through administration of a recombinant binding protein comprising an ankyrin repeat domain. In some embodiments, the composition may be administered every 8 weeks to every 16 weeks. In some embodiments, the patient being treated may be refractory to existing anti-VEGF therapies.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: February 25, 2020
    Assignee: Allergan, Inc.
    Inventor: Thomas Conlon Hohman
  • Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
    Patent number: 10555933
    Abstract: The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, (S) 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole or (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: February 11, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Mohammed I. Dibas, John E. Donello, Daniel W. Gil
  • Methods for treating osteoarthritis pain
    Patent number: 10537619
    Abstract: Methods for alleviating osteoarthritis-associated symptoms by selecting a treatment-eligible patient and local administration of a clostridial derivative, such as a botulinum toxin, to an osteoarthritis-affected site are disclosed herein.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: January 21, 2020
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Guang-Liang Jiang, Ronald E. DeGryse
  • Method of detecting cleaved SNAP25 in tissue samples
    Patent number: 10527620
    Abstract: Methods and compositions for detecting BoNT/A enzymatic activity in tissues or a tissue sample are described herein. The invention encompasses antibodies that bind preferentially to BoNT/A cleaved SNAP25 and is able to preferentially detect BoNT/A cleaved SNAP25, as compared to intact (non-cleaved) SNAP25, in a tissue sample.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: January 7, 2020
    Assignee: Allergan, Inc.
    Inventors: Ron S. Broide, Brian Cai, Ester Fernandez-Salas, Joseph Francis, Catherine Rheaume
  • Lighter weight implant
    Patent number: 10524897
    Abstract: A breast implant is provided which includes a filling, or core having a lower overall density relative to silicone gel-filled or saline-filled implant. The core may be a composite including flexible, bodies, for example, air-containing, or gas-containing, bodies, and a gel medium between or around the bodies.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: January 7, 2020
    Assignee: Allergan, Inc.
    Inventor: David Schuessler
  • Degradable clostridial toxins
    Patent number: 10501731
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 10, 2019
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Enamines and diastereo-selective reduction of enamines
    Patent number: 10501483
    Abstract: Described herein is a compound having a chemical structure of Formula A: wherein m, p, q, W, Z, Y, X1, X2, R1, R2, R3 and R4 are as defined herein. A diastereo-selective reduction of the compound comprising contacting the compound of Formula A with a reducing agent in an aprotic polar or non-polar solvent is also described.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: December 10, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Danny T. Dinh, William R. Perrault
  • Method for improving duration of effect of dermal filler treatment
    Patent number: 10493014
    Abstract: A method of treating midface volume deficit in a person is provided. The method generally includes administering a dermal filler, such as a hyaluronic acid based dermal filler, in a sequence of injections that enhance effectiveness and/or duration of the filler. The method may include initially introducing a volume of the filler into at a zygomaticomalar region of the face prior to introducing one or more additional volumes of the filler into the anteromedial region and the submalar region, such that the duration of effectiveness of the treatment is improved, and less filler is required to achieve a desired correction.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 3, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Diane K. Murphy, Deepali Paradkar-Mitragotri
  • 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 10493082
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: December 3, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
    Patent number: 10471004
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: November 12, 2019
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson
  • Syringe device
    Patent number: D865948
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: November 5, 2019
    Assignee: Allergan, Inc.
    Inventors: Bastien Mandaroux, Shushuo Wu, Lance Hussey
  • Syringe device
    Patent number: D865950
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: November 5, 2019
    Assignee: Allergan, Inc.
    Inventors: Bastien Mandaroux, Shushuo Wu, Lance Hussey
  • Syringe device
    Patent number: D866753
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: November 12, 2019
    Assignee: Allergan, Inc.
    Inventors: Bastien Mandaroux, Shushuo Wu, Lance Hussey
  • Syringe device
    Patent number: D867582
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: November 19, 2019
    Assignee: Allergan, Inc.
    Inventors: Bastien Mandaroux, Shushuo Wu, Lance Hussey